Takeda Pharmaceutical Co Ltd
TAK15.025USD
-0.084-0.56%
Fechamento 04/25, 16:00（ET）Cotações atrasadas em 15 min
23.82BValor de mercado
0.11P/L TTM
Mais detalhes de Takeda Pharmaceutical Co Ltd Empresa
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Informações da empresa
Código da empresaTAK
Nome da EmpresaTakeda Pharmaceutical Co Ltd
Data de listagemMay 16, 1949
Fundado em1925
CEOMr. Christophe Weber
Número de funcionários49281
Tipo de títulosDepository Receipt
Fim do ano fiscalMay 16
Endereço4F
CidadeCHUO-KU
Bolsa de valoresNYSE Consolidated
PaísJapan
Código postal103-8668
Telefone81332782111
Sitehttps://www.takeda.com/
Código da empresaTAK
Data de listagemMay 16, 1949
Fundado em1925
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Milano Furuta
Mr. Milano Furuta
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Masami Iijima
Mr. Masami Iijima
Chairman of Board of Directors, Independent Director
Chairman of Board of Directors, Independent Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Detalhamento da receita
Moeda: JPYTempo de atualização: dom, 6 de abr
Moeda: JPYTempo de atualização: dom, 6 de abr
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
Por EmpresaJPY
Nome
Receita
Proporção
Gastrointestinal diseases
344.12B
30.08%
Plasma derivatives
248.54B
21.72%
Rare diseases
190.32B
16.63%
Oncology
143.10B
12.51%
Neuroscience
141.94B
12.41%
Other
76.15B
6.66%
Por RegiãoJPY
Nome
Receita
Proporção
United States
593.84B
51.90%
Europe And Canada (Country)
262.60B
22.95%
Japan
108.34B
9.47%
Asia
69.19B
6.05%
Latin America
58.66B
5.13%
Other
51.53B
4.50%
Por Empresa
Por Região
Por EmpresaJPY
Nome
Receita
Proporção
Gastrointestinal diseases
344.12B
30.08%
Plasma derivatives
248.54B
21.72%
Rare diseases
190.32B
16.63%
Oncology
143.10B
12.51%
Neuroscience
141.94B
12.41%
Other
76.15B
6.66%
Acionista
Tempo de atualização: ter, 8 de abr
Tempo de atualização: ter, 8 de abr
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.16%
Arrowstreet Capital, Limited Partnership
0.14%
Fidelity Management & Research Company LLC
0.11%
First Trust Advisors L.P.
0.10%
Other
99.07%
Estatísticas dos acionistas
Acionista
Proporção
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.16%
Arrowstreet Capital, Limited Partnership
0.14%
Fidelity Management & Research Company LLC
0.11%
First Trust Advisors L.P.
0.10%
Other
99.07%
Tipo
Acionista
Proporção
Investment Advisor
1.55%
Investment Advisor/Hedge Fund
0.35%
Hedge Fund
0.27%
Research Firm
0.14%
Family Office
0.01%
Family Office
0.01%
Family Office
0.01%
Other
97.64%
Participação acionária institucional
Tempo de atualização: dom, 19 de jan
Tempo de atualização: dom, 19 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
574
73.02M
2.32%
-10.12M
2024Q4
595
73.56M
2.33%
-9.88M
2024Q3
583
77.60M
2.45%
-3.33M
2024Q2
581
73.43M
2.34%
-14.54M
2024Q1
593
78.98M
2.52%
-11.62M
2023Q4
609
83.80M
2.67%
-18.91M
2023Q3
621
81.24M
2.59%
-37.59M
2023Q2
617
84.64M
2.72%
-34.14M
2023Q1
627
84.81M
2.73%
-21.74M
2022Q4
637
69.93M
2.25%
-40.01M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Capital Research Global Investors
13.16M
0.42%
+25.31K
+0.19%
Dec 31, 2024
Parametric Portfolio Associates LLC
5.14M
0.16%
+961.51K
+23.02%
Dec 31, 2024
Arrowstreet Capital, Limited Partnership
4.22M
0.13%
-419.02K
-9.04%
Dec 31, 2024
Fidelity Management & Research Company LLC
3.33M
0.11%
+438.69K
+15.18%
Dec 31, 2024
First Trust Advisors L.P.
3.24M
0.1%
+62.72K
+1.97%
Dec 31, 2024
Renaissance Technologies LLC
3.08M
0.1%
-139.40K
-4.33%
Dec 31, 2024
Brandes Investment Partners, L.P.
3.04M
0.1%
-192.02K
-5.94%
Dec 31, 2024
Goldman Sachs Asset Management, L.P.
2.32M
0.07%
+131.24K
+6.01%
Dec 31, 2024
Van Eck Associates Corporation
2.21M
0.07%
+35.19K
+1.62%
Dec 31, 2024
Aperio Group, LLC
2.20M
0.07%
+313.03K
+16.56%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Nome
Proporção
VanEck Pharmaceutical ETF
4.7%
SGI Enhanced Global Income ETF
3.05%
Roundhill GLP-1 & Weight Loss ETF
2.1%
ActivePassive International Equity ETF
0.6%
First Trust Value Line Dividend Index Fund
0.45%
Pacer Trendpilot International ETF
0.26%
Avantis International Equity ETF
0.07%
Avantis Responsible International Equity ETF
0.07%
DFA Dimensional International Core Equity 2 ETF
0%
Pacer Developed Markets International Cash Cws 100
0%
Ver Mais
VanEck Pharmaceutical ETF
Proporção4.7%
SGI Enhanced Global Income ETF
Proporção3.05%
Roundhill GLP-1 & Weight Loss ETF
Proporção2.1%
ActivePassive International Equity ETF
Proporção0.6%
First Trust Value Line Dividend Index Fund
Proporção0.45%
Pacer Trendpilot International ETF
Proporção0.26%
Avantis International Equity ETF
Proporção0.07%
Avantis Responsible International Equity ETF
Proporção0.07%
DFA Dimensional International Core Equity 2 ETF
Proporção0%
Pacer Developed Markets International Cash Cws 100
Proporção0%
Dividendo
Um total de
1.42T
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sep 12, 2024
TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024
Sep 30, 2024
Dec 12, 2024
Sep 30, 2024
Mar 14, 2024
TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024
Mar 28, 2024
Jul 08, 2024
Mar 27, 2024
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados